Press release
Deadline on Feb. 18th coming up in Lawsuit for Investors in shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
A Deadline is coming up on February 18, 2022 in the lawsuit for certain investors in Reata Pharmaceuticals, Inc. (NASDAQ: RETA).
Investors who purchased shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) have certain options and there are strict and short deadlines running. Deadline: February 18, 2022. NASDAQ: RETA stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S. District Court for the Eastern District of Texas the plaintiff alleges on behalf of purchasers of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) common shares between November 9, 2020 and December 8, 2021, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between November 9, 2020 and December 8, 2021, the Defendants failed to disclose to investors that the FDA had raised concerns regarding the validity of the clinical study designed to measure the efficacy and safety of bardoxolone for the treatment of chronic kidney disease caused by Alport syndrome, that, as a result, there was a material risk that Reata's NDA would not be approved, and that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Those who purchased shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Deadline on Feb. 18th coming up in Lawsuit for Investors in shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) here
News-ID: 2555048 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Reata
Investigation for Long-Term Investors in shares of Reata Pharmaceuticals, Inc. ( …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Reata Pharmaceuticals, Inc.
Investors who are current long term investors in Reata Pharmaceuticals, Inc. (NASDAQ: RETA) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: RETA stocks follows a lawsuit filed against Reata Pharmaceuticals, Inc.…
Investigation announced for Investors in shares of Reata Pharmaceuticals, Inc. ( …
An investigation was announced over potential securities laws violations by Reata Pharmaceuticals, Inc. in connection with certain financial statements.
Investors who purchased shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Reata Pharmaceuticals, Inc. regarding its business, its prospects and its operations were…
Investigation for Long-Term Investors in shares of Reata Pharmaceuticals, Inc. ( …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Reata Pharmaceuticals, Inc..
Investors who are current long term investors in Reata Pharmaceuticals, Inc. (NASDAQ: RETA) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: RETA stocks follows a lawsuit filed against Reata…
Lawsuit filed for Investors in Reata Pharmaceuticals, Inc. (NASDAQ: RETA) shares
An investor, who purchased shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA), filed a lawsuit iover alleged violations of Federal Securities Laws by Reata Pharmaceuticals, Inc.
Investors who purchased shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) have certain options and for certain investors are short and strict deadlines running. Deadline: December 14, 2020. NASDAQ: RETA investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
On August 10, 2020,…
Investigation announced for Investors in Reata Pharmaceuticals, Inc. (NASDAQ: RE …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Reata Pharmaceuticals, Inc.
Investors who purchased shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Reata Pharmaceuticals, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.
Plano,…
Investigation announced for Investors in shares of Reata Pharmaceuticals, Inc. ( …
An investigation was announced concerning potential securities laws violations by Reata Pharmaceuticals, Inc. in connection with certain financial statements.
Investors who purchased shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Reata Pharmaceuticals, Inc. regarding its business, its prospects and its operations were…
